Inhibrx Biosciences, Inc.INBXNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank78
3Y CAGR+86.2%
5Y CAGR+11.2%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+86.2%/yr
vs -13.1%/yr prior
5Y CAGR
+11.2%/yr
Recent acceleration
Acceleration
+99.3pp
Accelerating
Percentile
P78
Within normal range
vs 5Y Ago
1.7x
Solid growth
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $136.32M | -58.6% |
| 2024 | $329.36M | +49.8% |
| 2023 | $219.83M | +940.8% |
| 2022 | $21.12M | +71.2% |
| 2021 | $12.34M | -84.6% |
| 2020 | $80.25M | +52.0% |
| 2019 | $52.81M | +42.7% |
| 2018 | $37.01M | +33.7% |
| 2017 | $27.68M | +49.1% |
| 2016 | $18.56M | - |